FEMSA Analysts Turn Constructive Ahead of Tuesday Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Among Latin American consumer names, FMX carries one of the lighter short footprints in the peer group. Arca Continental and Ambev both trade with meaningfully higher short interest ratios. FEMSA's own short position amounts to roughly 1.8 million shares, a figure that has drifted lower over the past month and sits well below levels that would attract squeeze attention.
Analyst conviction has shifted notably in the past two weeks. JP Morgan lifted its target from $126 to $151 on October 16, keeping an Overweight rating, and UBS followed on October 23 by raising its own target to $134, though the firm held at Neutral. That puts the Street consensus mean at $135, a little above Thursday's close of $128.52. The divergence between JP Morgan's $151 and UBS's $134 captures the actual debate: whether FEMSA's retail and proximity store margins can recover fast enough to justify a re-rating, or whether the structural drag on that segment limits upside to a modest premium over current levels. Bank of America upgraded to Buy in August with a $150 target, adding a third voice on the constructive side. UBS, which had previously rated the stock Buy, stepped back to Neutral that same week, so the bull camp has grown but is not unanimous.
The last two earnings prints show why positioning is cautious rather than euphoric. The July 2026 quarter delivered an 8.4% single-day decline. The April print reversed that entirely, with a 7.1% gain on the day and a further 7.1% over the following five sessions. The stock is up 5.3% over the past month and 1.6% over the past week, so it goes into Tuesday from a position of modest recent strength rather than distress. Options positioning leans bullish: the put/call ratio has dropped to 0.03, well below its 20-day average of 0.08, and the z-score of negative 1.1 points to call-side dominance that mirrors the more constructive analyst tone. Borrow costs have collapsed from a brief spike above 4% on October 14 to just 0.09% now, and share availability is extraordinarily loose, so there is no friction in the lending market to complicate positioning either way.
One activist-register item is worth carrying: Cascade Investment, L.L.C. filed a Schedule 13D in April 2026 disclosing a 14% stake. A 13D signals active intent rather than passive ownership, making Cascade a potentially influential voice on strategy. As with all 13D/G disclosures, the stake is as-last-reported and positions can change without a further filing once they move below the 5% threshold.
Tuesday's print will test whether FEMSA's operational momentum in beverages is sufficient to offset the retail margin story that kept UBS on the sidelines even as it raised its target.
Stocks in this article
See the live data behind this article on ORTEX.
Open FMX on ORTEX →How this article was generated
- Generated
- 24 Oct 2026, 04:07
- Data as of
- 24 Oct 2026, 04:00
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.